Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2'-((4'-trifluoromethanesulfonyloxy)phenyl)-n-methanesulfonylpropionamide
2. Df 2156a
3. Df 2156y
4. Df-2156a
5. Df-2156y
6. Df2156a
7. Df2156y
1. 849776-05-2
2. Ladarixin [inn]
3. (r)-4-[1-(methylsulfonamido)-1-oxo-2-propyl]phenyl Trifluoromethanesulfonate
4. 4-((2r)-1-oxo-1-(methanesulfonamido)propan-2-yl)phenyl Trifluoromethanesulfonate
5. Deh7q6472o
6. 849776-05-2 (free)
7. Methanesulfonic Acid, 1,1,1-trifluoro-, 4-((1r)-1-methyl-2-((methylsulfonyl)amino)-2-oxoethyl)phenyl Ester
8. Methanesulfonic Acid, Trifluoro-, 4-((1r)-1-methyl-2-((methylsulfonyl)amino)-2-oxoethyl)phenyl Ester
9. Df2156a
10. Unii-deh7q6472o
11. Ladarixin [who-dd]
12. Schembl251618
13. Chembl189475
14. Dtxsid50234030
15. Df-2156a
16. Ac6925
17. Bdbm50475370
18. Akos037649625
19. Cs-12792
20. Hy-19519
21. Cs-0015618
22. A857904
23. Q27276351
24. (r)-(-)-n-(2-(4-(trifluoromethanesulfonyloxy)phenyl)propionyl)methanesulfonamide
25. [4-[(2r)-1-(methanesulfonamido)-1-oxopropan-2-yl]phenyl] Trifluoromethanesulfonate
| Molecular Weight | 375.3 g/mol |
|---|---|
| Molecular Formula | C11H12F3NO6S2 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 375.00581394 g/mol |
| Monoisotopic Mass | 375.00581394 g/mol |
| Topological Polar Surface Area | 123 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 624 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of type I diabetes mellitus
ABOUT THIS PAGE
A Ladarixin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ladarixin, including repackagers and relabelers. The FDA regulates Ladarixin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ladarixin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ladarixin supplier is an individual or a company that provides Ladarixin active pharmaceutical ingredient (API) or Ladarixin finished formulations upon request. The Ladarixin suppliers may include Ladarixin API manufacturers, exporters, distributors and traders.
Ladarixin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ladarixin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ladarixin GMP manufacturer or Ladarixin GMP API supplier for your needs.
A Ladarixin CoA (Certificate of Analysis) is a formal document that attests to Ladarixin's compliance with Ladarixin specifications and serves as a tool for batch-level quality control.
Ladarixin CoA mostly includes findings from lab analyses of a specific batch. For each Ladarixin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ladarixin may be tested according to a variety of international standards, such as European Pharmacopoeia (Ladarixin EP), Ladarixin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ladarixin USP).
LOOKING FOR A SUPPLIER?
